Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg - capsule - 60 mg - active: atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg - capsule - 80 mg - active: atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black iron oxide red iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 149.4 mg (equivalent: lanreotide, qty 125.5 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 113.6 mg (equivalent: lanreotide, qty 95.4 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate, quantity: 77.9 mg (equivalent: lanreotide, qty 65.4 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 50.69 mg (equivalent: cabozantinib, qty 40 mg) - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; hypromellose; croscarmellose sodium; iron oxide yellow; hyprolose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; triacetin - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 25.34 mg (equivalent: cabozantinib, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; triacetin; titanium dioxide; lactose; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; croscarmellose sodium; hypromellose; iron oxide yellow - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - melatonin 2mg;   - modified release tablet - 2 mg - active: melatonin 2mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate methacrylic acid copolymer purified talc - indicated as a monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 years and over.

États-Unis - anglais - NLM (National Library of Medicine)

burel pharmaceuticals, inc. - methocarbamol (unii: 125od7737x) (methocarbamol - unii:125od7737x) - methocarbamol tablets, usp are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. methocarbamol does not directly relax tense skeletal muscles in man. methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

samsung bioepis nz limited - trastuzumab 150mg - powder for infusion concentrate - 150 mg - active: trastuzumab 150mg excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose dihydrate - metastatic breast cancer ontruzant is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: · as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; or · in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or · in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.